Skip to content
The Kids Research Institute Australia logo
Donate

Search

Group A Streptococcal Diseases and Their Global Burden

We review GAS transmission characteristics and prevention strategies, historical and geographical trends and report on the estimated global burden disease...

The Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (2nd edition)

Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) occur at very high rates among Aboriginal and Torres Strait Islander people.

Progress toward a global Group A streptococcal vaccine

The desire for an effective vaccine arises from the large burden of disease caused by the bacterium, particularly rheumatic fever and rheumatic heart disease.

Group A streptococcal vaccines: Paving a path for accelerated development

Vaccine prevention of GAS infections and their immunological complications has been a goal of researchers for decades.

The second rheumatic heart disease forum report

Building on the foundation of the first RHD forum, over 150 interested participants met to discuss critical issues on the RHD landscape.

Rheumatic Fever Follow-Up Study (RhFFUS) protocol: A cohort study investigating the significance of minor

In Australia, rheumatic heart disease (RHD) is almost exclusively restricted to Aboriginal Australian and Torres Strait Islander people with children being...

Evolution, Evidence and Effect of Secondary Prophylaxis Against Rheumatic Fever

The association between group A streptococcal infection and rheumatic fever (RF) was established in the early 20th century.

Disparity in Mortality From Rheumatic Heart Disease in Indigenous Australians

This study was undertaken to provide a comprehensive examination of rheumatic heart disease mortality rates and trends in Indigenous Australians.

Myositis complicating benzathine penicillin-G injection in a case of rheumatic heart disease

A 7-year old boy developed myositis secondary to intramuscular injection of benzathine penicillin-G in the context of secondary prophylaxis for RF